Evidence map›Paper›PMID 28035073›Full record

ArticleOncotarget2017

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.

Hyojin Kim, Jeong Mi Yang, Yan Jin, Sanghoon Jheon, Kwhanmien Kim, Choon Taek Lee, Jin-Haeng Chung, Jin Ho Paik

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. A review on the role of miR-671 in human disorders.Frontiers in molecular biosciences · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hyojin KimDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Jeong Mi YangDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Yan JinDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Sanghoon JheonDepartment of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
Kwhanmien KimDepartment of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
Choon Taek LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Jin-Haeng ChungDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Jin Ho PaikDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Seoul National University Bundang Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma has distinctive clinicopathological features that are related to specific genetic alterations, including EGFR and KRAS mutations and ALK rearrangement. MicroRNAs are small non-coding RNAs that post-transcriptionally regulate many important biological processes and influence cancer phenotypes. This study retrospectively investigated microRNA expression profiles, and their clinicopathological implications, in lung adenocarcinoma according to genetic status (EGFR, KRAS, ALK, and triple negative). A total of 72 surgically resected lung adenocarcinoma specimens (19 EGFR-mutated, 17 KRAS-mutated, 16 ALK-rearranged, and 20 triple negative cancers) were screened for 23 microRNAs using quantitative real-time reverse transcriptase polymerase chain reaction. We then evaluated the associations between the microRNA expressions and the cancers' genetic and clinicopathological features. Eight microRNAs were associated with clinicopathological features, such as male sex and ever-smoker status (high miR-373-3p, miR-1343-3p, miR-138-1-3p, and miR-764; low miR-27b-3p) and vascular invasion (high miR-27b-3p; low miR-1343-3p and miR-764). Clustering and discriminant analyses revealed that the microRNA expression patterns in the ALK group were different from those in the EGFR and KRAS groups. Five microRNAs (high miR-1343-3p; low miR-671-3p, miR-103a-3p, let-7e, and miR-342-3p) were especially distinctive in the ALK group, compared to the EGFR and KRAS groups. Moreover, a significant association was observed between ALK-rearrangement, decreased miR-342-3p expression, and immunohistochemical loss of E-cadherin. Therefore, microRNA expression profiles appear to have distinctive clinicopathological implications in ALK-rearranged lung adenocarcinoma. Furthermore, the association of ALK rearrangement, decreased miR-342-3p expression, and E-cadherin loss might indicate that miR-342-3p is involved in the ALK-associated phenotypes and epithelial-mesenchymal transition.

Indexed as

TranscriptomeAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseAntigens, CDBiomarkers, TumorCadherinsCluster AnalysisDiscriminant AnalysisEpithelial-Mesenchymal TransitionErbB ReceptorsFemaleGene Expression ProfilingALK protein, humanAnaplastic Lymphoma KinaseAntigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanEGFR protein, humanErbB ReceptorsKRAS protein, humanMicroRNAsMIRN342 microRNA, humanProto-Oncogene Proteins p21(ras)Receptor Protein-Tyrosine KinasesadenocarcinomaALKlung cancermicroRNAmiR-342-3p

Identifiers

PMID28035073
PMCPMC5352416
OpenAlexW2561181433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.